Paul A. Hamlin, MD
The 2017 ASH Annual Meeting brought to light the expansive impact that chimeric antigen receptor (CAR) T-cell therapy has had on patients with large cell lymphoma, but it also highlighted how much work remains in this space, according to Paul A. Hamlin, MD.
In the longer follow-up of the phase II ZUMA-1 trial, axicabtagene ciloleucel (axi-cel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). In the updated assessment, which was a 1-year follow-up of ZUMA-1, 42% of patients treated with axi-cel remained progression free and 56% were alive. The 18-month progression-free survival (PFS) rate was 41% and the 18-month overall survival rate was 52%.
... to read the full story